Wuhan YZY Biopharma Co EBIT

Wuhan YZY Biopharma Co (2496.HK) currently reports a EBIT of $-45M as of June 2026. That compares with $-75M in the prior-year period — up 39.5% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore Wuhan YZY Biopharma Co's EBIT history and peer comparisons.

Wuhan YZY Biopharma Co's EBIT increased from $-75M to $-45M — a 39.5% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Wuhan YZY Biopharma Co's EBIT of $-45M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

Wuhan YZY Biopharma Co reported $-45M in EBIT as of June 2026. That compares with $-75M in the prior-year period — up 39.5% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current EBIT of $-45M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for Wuhan YZY Biopharma Co, and consider following 2496.HK for alerts when major investors trade the stock.